Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Pares R&D Areas By 25 Percent, But Will Continue Licensing

Executive Summary

Following through on its R&D reduction pledge, AstraZeneca is calling off its own discovery efforts in 10 specific disease areas, though the company insists it will continue to pursue in-licensing deals in these therapeutic areas

You may also be interested in...



Sounding The Alarm On The Future Of CNS Drug Development

The drug development paradigm for new central nervous system therapeutics is in need of a thorough reimagining, Tufts Center for the Study of Drug Development researchers assert in an analysis published in Scientific American.

Sounding The Alarm On The Future Of CNS Drug Development

The drug development paradigm for new central nervous system therapeutics is in need of a thorough reimagining, Tufts Center for the Study of Drug Development researchers assert in an analysis published in Scientific American.

At PSA, Meet The New Deal-Makers (Part 1)

Two of the biopharma industry's newest heads of business development talked with Elsevier Business Intelligence Editor-in-Chief Chris Morrison at the Pharmaceutical Strategic Alliances conference on Sept. 22 in New York.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051993

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel